{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:31:20Z","timestamp":1792690280300,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04293-8","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:33:14Z","timestamp":1773484394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fibroblast-associated CTHRC1 as a key indicator of recurrence risk in prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoteng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keruo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shida","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KeFei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"3","key":"4293_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10305","key":"4293_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398(10305):1075\u201390.","journal-title":"Lancet"},{"issue":"5","key":"4293_CR3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","volume":"69","author":"RC van den Bergh","year":"2016","unstructured":"van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol. 2016;69(5):802\u201320.","journal-title":"Eur Urol"},{"issue":"4","key":"4293_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part ii: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"4","key":"4293_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"key":"4293_CR6","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1016\/j.csbj.2021.08.046","volume":"19","author":"BB Lin","year":"2021","unstructured":"Lin BB, Lei HQ, Xiong HY, Fu X, Shi F, Yang XW, et al. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. Comput Struct Biotechnol J. 2021;19:4941\u201353.","journal-title":"Comput Struct Biotechnol J"},{"issue":"22","key":"4293_CR7","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1158\/1078-0432.CCR-19-1587","volume":"25","author":"DE Spratt","year":"2019","unstructured":"Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, et al. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer. Clin Cancer Res. 2019;25(22):6721\u201330.","journal-title":"Clin Cancer Res"},{"key":"4293_CR8","doi-asserted-by":"crossref","unstructured":"Naser R, Fakhoury I, El-Fouani A, Abi-Habib R, El-Sibai M. Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review). Int J Oncol. 2023;62(2):23.","DOI":"10.3892\/ijo.2022.5471"},{"issue":"1","key":"4293_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","volume":"21","author":"I Heidegger","year":"2022","unstructured":"Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer. 2022;21(1):132.","journal-title":"Mol Cancer"},{"issue":"1","key":"4293_CR10","doi-asserted-by":"publisher","first-page":"2029298","DOI":"10.1080\/2162402X.2022.2029298","volume":"11","author":"M Hagiwara","year":"2022","unstructured":"Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, et al. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology. 2022;11(1):2029298.","journal-title":"Oncoimmunology"},{"key":"4293_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.critrevonc.2017.02.026","volume":"113","author":"MC Maia","year":"2017","unstructured":"Maia MC, Hansen AR. A comprehensive review of immunotherapies in prostate cancer. Crit Rev Oncol Hematol. 2017;113:292\u2013303.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4293_CR12","doi-asserted-by":"crossref","unstructured":"Bizzarri FP, Campetella M, Russo P, Palermo G, Moosavi SK, Rossi F, et al. Prognostic value of PLR, SIRI, PIV, SII, and NLR in non-muscle invasive bladder cancer: can inflammatory factors influence pathogenesis and outcomes? Cancers (Basel). 2025;17(13):2189.","DOI":"10.3390\/cancers17132189"},{"issue":"1","key":"4293_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-025-06236-5","volume":"23","author":"Y Lu","year":"2025","unstructured":"Lu Y, Chen Y, Wang Z, Shen H, Xu L, Huang C, et al. Single-cell and spatial transcriptome profiling reveal CTHRC1\u2009+\u2009fibroblasts promote EMT through WNT5A signaling in colorectal cancer. J Transl Med. 2025;23(1):282.","journal-title":"J Transl Med"},{"issue":"1","key":"4293_CR14","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022;13(1):6036.","journal-title":"Nat Commun"},{"issue":"12","key":"4293_CR15","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-13-2699","volume":"74","author":"Q Long","year":"2014","unstructured":"Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74(12):3228\u201337.","journal-title":"Cancer Res"},{"key":"4293_CR16","doi-asserted-by":"crossref","unstructured":"Chen S, Zhu GA-O, Yang Y, Wang FA-O, Xiao YA-O, Zhang N, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23(1):87\u201398.","DOI":"10.1038\/s41556-020-00613-6"},{"issue":"12","key":"4293_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739\u201340.","journal-title":"Bioinformatics"},{"issue":"5","key":"4293_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"1","key":"4293_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"W1","key":"4293_CR20","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"4293_CR21","doi-asserted-by":"crossref","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573\u2013e8729.","DOI":"10.1016\/j.cell.2021.04.048"},{"issue":"2","key":"4293_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"1","key":"4293_CR23","doi-asserted-by":"publisher","first-page":"15608","DOI":"10.1038\/s41598-018-34129-9","volume":"8","author":"ME Han","year":"2018","unstructured":"Han ME, Kim JY, Kim GH, Park SY, Kim YH, Oh SO. SAC3D1: a novel prognostic marker in hepatocellular carcinoma. Sci Rep. 2018;8(1):15608.","journal-title":"Sci Rep"},{"issue":"3","key":"4293_CR24","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1002\/jcb.27699","volume":"120","author":"SH Cho","year":"2019","unstructured":"Cho SH, Pak K, Jeong DC, Han ME, Oh SO, Kim YH. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma. J Cell Biochem. 2019;120(3):4140\u20136.","journal-title":"J Cell Biochem"},{"issue":"8","key":"4293_CR25","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1111\/jcmm.16321","volume":"25","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Guan G, Cheng P, Cheng W, Yang L, Wu A. Characterization of an endoplasmic reticulum stress-related signature to evaluate immune features and predict prognosis in glioma. J Cell Mol Med. 2021;25(8):3870\u201384.","journal-title":"J Cell Mol Med"},{"key":"4293_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jsbmb.2015.05.010","volume":"153","author":"TM Penning","year":"2015","unstructured":"Penning TM. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol. 2015;153:105\u201313.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"4293_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313.","journal-title":"Nat Med"},{"issue":"2","key":"4293_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400\u201316. e11.","journal-title":"Cell"},{"key":"4293_CR29","doi-asserted-by":"crossref","unstructured":"Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179.","DOI":"10.1101\/cshperspect.a026179"},{"key":"4293_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375\u2013404.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"4293_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41388-021-01903-5","volume":"41","author":"JJ McCann","year":"2022","unstructured":"McCann JJ, Vasilevskaya IA, McNair C, Gallagher P, Neupane NP, de Leeuw R, et al. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene. 2022;41(3):444\u201358.","journal-title":"Oncogene"},{"key":"4293_CR32","doi-asserted-by":"publisher","first-page":"1009634","DOI":"10.3389\/fimmu.2022.1009634","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Zheng Y, Jiang C, Yang C, Zhang L, Liang C. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies. Front Immunol. 2022;13:1009634.","journal-title":"Front Immunol"},{"issue":"6","key":"4293_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","volume":"25","author":"B De Laere","year":"2019","unstructured":"De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(6):1766\u201373.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4293_CR34","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/ATVBAHA.121.316450","volume":"41","author":"EM Nordquist","year":"2021","unstructured":"Nordquist EM, Dutta P, Kodigepalli KM, Mattern C, McDermott MR, Trask AJ, et al. Tgfbeta1-Cthrc1 signaling plays an important role in the short-term reparative response to heart valve endothelial injury. Arterioscler Thromb Vasc Biol. 2021;41(12):2923\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"4293_CR35","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1172\/JCI69493","volume":"123","author":"S Takeshita","year":"2013","unstructured":"Takeshita S, Fumoto T, Matsuoka K, Park KA, Aburatani H, Kato S, et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest. 2013;123(9):3914\u201324.","journal-title":"J Clin Invest"},{"issue":"4","key":"4293_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jama.2011.1029","volume":"306","author":"M Orloff","year":"2011","unstructured":"Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang YR, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011;306(4):410\u20139.","journal-title":"JAMA"},{"issue":"2","key":"4293_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/01.RES.0000154262.07264.12","volume":"96","author":"P Pyagay","year":"2005","unstructured":"Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005;96(2):261\u20138.","journal-title":"Circ Res"},{"issue":"1","key":"4293_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.devcel.2008.05.007","volume":"15","author":"S Yamamoto","year":"2008","unstructured":"Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell. 2008;15(1):23\u201336.","journal-title":"Dev Cell"},{"issue":"23","key":"4293_CR39","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41388-021-01827-0","volume":"40","author":"XL Zhang","year":"2021","unstructured":"Zhang XL, Hu LP, Yang Q, Qin WT, Wang X, Xu CJ, et al. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer. Oncogene. 2021;40(23):3959\u201373.","journal-title":"Oncogene"},{"issue":"1","key":"4293_CR40","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41598-021-81819-y","volume":"11","author":"M Chauvin","year":"2021","unstructured":"Chauvin M, Garambois V, Colombo PE, Chentouf M, Gros L, Brouillet JP, et al. Anti-Mullerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. Sci Rep. 2021;11(1):2231.","journal-title":"Sci Rep"},{"issue":"7","key":"4293_CR41","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamaophthalmol.2021.0385","volume":"139","author":"D Rechsteiner","year":"2021","unstructured":"Rechsteiner D, Issler L, Koller S, Lang E, Bahr L, Feil S, et al. Genetic analysis in a swiss cohort of bilateral congenital cataract. JAMA Ophthalmol. 2021;139(7):691\u2013700.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"4293_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12957-022-02557-7","volume":"20","author":"C Meng","year":"2022","unstructured":"Meng C, Zhang Y, Jiang D, Wang J. CTHRC1 is a prognosis-related biomarker correlated with immune infiltrates in colon adenocarcinoma. World J Surg Oncol. 2022;20(1):89.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"4293_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbrc.2020.02.098","volume":"525","author":"Z Ma","year":"2020","unstructured":"Ma Z, Chao F, Wang S, Song Z, Zhuo Z, Zhang J, et al. CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. Biochem Biophys Res Commun. 2020;525(2):418\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4293_CR44","doi-asserted-by":"publisher","first-page":"19873","DOI":"10.1038\/s41598-021-99321-w","volume":"11","author":"N Sial","year":"2021","unstructured":"Sial N, Ahmad M, Hussain MS, Iqbal MJ, Hameed Y, Khan M, et al. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci Rep. 2021;11(1):19873.","journal-title":"Sci Rep"},{"issue":"1","key":"4293_CR45","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1186\/s12885-022-09951-0","volume":"22","author":"Z Jiao","year":"2022","unstructured":"Jiao Z, Feng X, Cui Y, Wang L, Gan J, Zhao Y, et al. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer. BMC Cancer. 2022;22(1):871.","journal-title":"BMC Cancer"},{"issue":"1\u20136","key":"4293_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08977194.2021.1994964","volume":"39","author":"AM Garcia Muro","year":"2021","unstructured":"Garcia Muro AM, Garcia Ruvalcaba A, de la Rizo LDC, Sanchez Lopez JY. Role of the BMP6 protein in breast cancer and other types of cancer. Growth Factors. 2021;39(1\u20136):1\u201313.","journal-title":"Growth Factors"},{"issue":"19\u201320","key":"4293_CR47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.cca.2010.05.040","volume":"411","author":"U Deligezer","year":"2010","unstructured":"Deligezer U, Yaman F, Darendeliler E, Dizdar Y, Holdenrieder S, Kovancilar M, et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta. 2010;411(19\u201320):1452\u20136.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"4293_CR48","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/bjc.2014.23","volume":"110","author":"GT Lee","year":"2014","unstructured":"Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer. 2014;110(6):1634\u201344.","journal-title":"Br J Cancer"},{"issue":"18","key":"4293_CR49","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1002\/cam4.4092","volume":"10","author":"Q Su","year":"2021","unstructured":"Su Q, Liu Z, Chen C, Gao H, Zhu Y, Wang L, et al. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy. Cancer Med. 2021;10(18):6492\u2013502.","journal-title":"Cancer Med"},{"issue":"11","key":"4293_CR50","doi-asserted-by":"publisher","first-page":"11345","DOI":"10.3934\/mbe.2022528","volume":"19","author":"Y Luo","year":"2022","unstructured":"Luo Y, Liu X, Lin J, Zhong W, Chen Q. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy. Math Biosci Eng. 2022;19(11):11345\u201366.","journal-title":"Math Biosci Eng"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04293-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:05:06Z","timestamp":1776834306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4293"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04293-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}